Eugenia Galindo Ramos, MD
Nephrology · Caguas, PRNPI 1689661894
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,930 of the $7,133 with a category attached, or 69.1%. 20 manufacturers reported payments, led by Johnson & Johnson at 32.7% of the total. Reporting peaked in 2019 at $2,901 and has fallen 78.0% since, to $640 in 2025. Among nephrology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $85.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AstraZeneca$1K
- Mallinckrodt Hospital Products Inc.$506
- Bayer$431
- Amgen$385
- Nxstage Medical, Inc.$339
- plus $2K from 14 others
Across 344 payments — averaging $1045.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$352K
- AbbVie$7K
- Merck$500
- Janssen Research & Development, LLC$112
What the payments were for
- Consulting fees$2,04029%
- Travel & lodging$220%
- Food & beverage$4,93069%
- Education$1412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $2,330 |
| AstraZeneca(2 entities) | 28 | $1,144 |
| Mallinckrodt Hospital Products Inc. | 8 | $506 |
| Bayer | 10 | $431 |
| Amgen(2 entities) | 5 | $385 |
| Nxstage Medical, Inc. | 2 | $339 |
| GSK | 4 | $336 |
| Bard Peripheral Vascular, Inc. | 2 | $214 |
| Fresenius USA Marketing, Inc. | 3 | $197 |
| Calliditas Therapeutics US Inc. | 2 | $192 |
| Travere Therapeutics, Inc. | 2 | $149 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Novo Nordisk | 1 | $121 |
| Kyowa Kirin, Inc. | 1 | $119 |
| Sanofi | 2 | $118 |
| Mallinckrodt Enterprises LLC | 1 | $100 |
| Vifor Pharma, Inc. | 1 | $100 |
| Boston Scientific | 1 | $99 |
| Apellis Pharmaceuticals, Inc. | 1 | $86 |
| Medtronic | 2 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,133 in reported general payments places this provider in the 90th percentile of 161 nephrology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lanthanum Carbonate | 62 | $29,003 |
| Sevelamer Carbonate | 190 | $25,530 |
| FarxigaDapagliflozin Propanediol | 29 | $19,255 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $11,582 |
| JardianceEmpagliflozin | 11 | $8,061 |
| Midodrine Hcl | 13 | $464 |
| Hydroxychloroquine Sulfate | 13 | $301 |
| Gabapentin | 26 | $220 |
| Nifedipine ErNifedipine | 16 | $186 |
| Hydroxyzine Pamoate | 23 | $159 |
| Atorvastatin Calcium | 15 | $96 |
| Tamsulosin Hcl | 11 | $84 |
| Lisinopril | 15 | $74 |
| Levothyroxine Sodium | 11 | $68 |
| Pantoprazole Sodium | 11 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,144 | $30,83843 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 161 nephrology providers in Puerto Rico.
Other nephrology in Caguas
- Jesse Diaz CorreaCaguas$5K
- Enrique AcostaCaguas$4K
- Jacobo Loyola-TorresCaguas$3K
- Ricardo Calderon OrtizCaguas$3K
- Moises Ortiz VillalobosCaguas$3K
- Rafael Baquero AlvarezCaguas$3K
- Eddie Rodriguez CastroToa Baja$591K
- William Hurtado-SantiagoMayaguez$191K
- William Vega OcasioCayey$40K
- Felix Perez RamosPonce$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.